A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Ariad Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Ariad Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01449461
First received: September 30, 2011
Last updated: April 11, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
No publications provided by Ariad Pharmaceuticals

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):